Overall survival and updated progression-free survival outcomes in a randomized phase II study of combination cediranib and olaparib versus olaparib in relapsed platinum-sensitive ovarian cancer-Reference-Cited by-同舟云学术

Overall survival and updated progression-free survival outcomes in a randomized phase II study of combination cediranib and olaparib versus olaparib in relapsed platinum-sensitive ovarian cancer

Published:2019-04 Issue:4 Volume:30 Page:551-557
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Liu J.F.,Barry W.T.,Birrer M.,Lee J.-M.,Buckanovich R.J.,Fleming G.F.,Rimel B.J.,Buss M.K.,Nattam S.R.,Hurteau J.,Luo W.,Curtis J.,Whalen C.,Kohn E.C.,Ivy S.P.,Matulonis U.A.

Funder

National Cancer Institute

NCI

National Institutes of Health

NIH

American Recovery and Reinvestment Act

Intramural Program of the Center for Cancer Research

Division of Cancer Treatment and Diagnosis

Publisher

Elsevier BV

Subject

Oncology,Hematology

Link

http://academic.oup.com/annonc/article-pdf/30/4/551/28564958/mdz018.pdf

Reference26 articles.

1. Cancer statistics, 2018;Siegel;CA Cancer J Clin,2018

2. Zejula (niraparib) [package insert]; https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208447lbl.pdf (29 January 2019, date last accessed).

3. Zejula (niraparib) [EMA Authorisation]; https://www.ema.europa.eu/en/medicines/human/EPAR/zejula (29 January 2019, date last accessed).

4. Lynparza (olaparib) [package insert]; https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/208558s001lbl.pdf (29 January 2019, date last accessed).

5. Rubraca (rucaparib) [package insert]; https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/209115s003lbl.pdf (29 January 2019, date last accessed).

Cited by 142 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficacy and safety of VEGFR inhibitors for recurrent ovarian cancer: a systematic review;Future Oncology;2024-08-12

2. Combined strategies with PARP inhibitors for the treatment of BRCA wide type cancer;Frontiers in Oncology;2024-08-02

3. A phase 2 trial exploring the significance of homologous recombination status in patients with platinum sensitive or platinum resistant relapsed ovarian cancer receiving combination cediranib and olaparib;Gynecologic Oncology;2024-08

4. FLT1 activation in cancer cells promotes PARP-inhibitor resistance in breast cancer;EMBO Molecular Medicine;2024-07-02

5. New hopes and promises in the treatment of ovarian cancer focusing on targeted treatment—a narrative review;Frontiers in Pharmacology;2024-06-14